162 related articles for article (PubMed ID: 37602448)
1. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors.
Pipe SW; Dunn AL; Young G
Expert Rev Hematol; 2023; 16(10):715-729. PubMed ID: 37602448
[TBL] [Abstract][Full Text] [Related]
2. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Escobar M; Luck J; Averianov Y; Ducore J; Fernández MFL; Giermasz A; Hart DP; Journeycake J; Kessler C; Leissinger C; Mahlangu J; Martinez LV; Miesbach W; Mitha IH; Quon D; Reding MT; Schved JF; Stasyshyn O; Vilchevska KV; Wang M; Windyga J; Alexander WA; Al-Sabbagh A; Bonzo D; Mitchell IS; Wilkinson TA; Hermans C
Haemophilia; 2021 Nov; 27(6):911-920. PubMed ID: 34614267
[TBL] [Abstract][Full Text] [Related]
3. Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice.
Ciolek AM; Arnall J; Moore DC; Palkimas S; Der-Nigoghossian J; Dane K
Ann Pharmacother; 2022 Jul; 56(7):831-838. PubMed ID: 34595941
[TBL] [Abstract][Full Text] [Related]
4. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
Pipe SW; Hermans C; Chitlur M; Carcao M; Castaman G; Davis JA; Ducore J; Dunn AL; Escobar M; Journeycake J; Khan O; Mahlangu J; Meeks SL; Mitha IH; Négrier C; Nowak-Göttl U; Recht M; Chrisentery-Singleton T; Stasyshyn O; Vilchevska KV; Martinez LV; Wang M; Windyga J; Young G; Alexander WA; Bonzo D; Macie C; Mitchell IS; Sauty E; Wilkinson TA; Shapiro AD
Haemophilia; 2022 Jul; 28(4):548-556. PubMed ID: 35475308
[TBL] [Abstract][Full Text] [Related]
5. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
[TBL] [Abstract][Full Text] [Related]
6. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.
Biron-Andreani C; Schved JF
Expert Rev Hematol; 2019 Jan; 12(1):21-28. PubMed ID: 30577721
[TBL] [Abstract][Full Text] [Related]
7. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
[TBL] [Abstract][Full Text] [Related]
8. Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia.
Watson N; Al-Samkari H
Drugs Today (Barc); 2022 Mar; 58(3):105-116. PubMed ID: 35274630
[TBL] [Abstract][Full Text] [Related]
9. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective.
Miesbach W; Carcao M; Mahlangu J; Dargaud Y; Jimenez-Yuste V; Hermans C
Haemophilia; 2024 Mar; 30(2):257-266. PubMed ID: 38317441
[TBL] [Abstract][Full Text] [Related]
10. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Escobar M; Castaman G; Boix SB; Callaghan M; de Moerloose P; Ducore J; Hermans C; Journeycake J; Leissinger C; Luck J; Mahlangu J; Miesbach W; Mitha IH; Négrier C; Quon D; Recht M; Schved JF; Shapiro AD; Sidonio R; Srivastava A; Stasyshyn O; Vilchevska KV; Wang M; Young G; Alexander WA; Al-Sabbagh A; Bonzo D; Macie C; Wilkinson TA; Kessler C
Haemophilia; 2021 Nov; 27(6):921-931. PubMed ID: 34636112
[TBL] [Abstract][Full Text] [Related]
11. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
Croom KF; McCormack PL
BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
[TBL] [Abstract][Full Text] [Related]
13. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
14. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
[TBL] [Abstract][Full Text] [Related]
15. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
[TBL] [Abstract][Full Text] [Related]
17. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
Stephens JM; Joshi AV; Sumner M; Botteman MF
Expert Opin Pharmacother; 2007 Jun; 8(8):1127-36. PubMed ID: 17516876
[TBL] [Abstract][Full Text] [Related]
18. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
[TBL] [Abstract][Full Text] [Related]
19. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
[TBL] [Abstract][Full Text] [Related]
20. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.
Meeks SL; Batsuli G
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):657-662. PubMed ID: 27913543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
